2022 Guidance and E.S.G. Considerations

2022 Guidance Considerations EBITDA impacted by continued Hospice length of stay pressures, incremental Contessa investments, incentive compensation and costs related to Omicron Amedisys Consolidated Home Health Hospice Personal Care • Tax rate 27% • Cash tax rate ~19% • • Diluted share count ~33.2 million shares Capital Expenditures ~$7-$9 million • Salary increase ~2% -3% • Benefits increase ~11% (8% growth/headcount, 3% pricing / claims costs) Overall $8 million investment in business development resources • Excludes future acquisitions, related integration costs and potential share repurchase • Total same store admission growth: ~5% . Continued investment in business development staffing to support growth ~$4 million Continued focus on Quality of Care (Stars and Acute Care Hospitalization rates) • +3.2% rate increase • Total same store admission growth: ~13% • Addition of business development resources to support ADC growth ~ $4 million • +2.0% rate increase • Total billable hours growth: -3% Personal Care Network to drive $2M revenue to ~ Home Health and Hospice combined High Acuity Care • 5 new Joint Venture • arrangements in 2022 ⚫ $56M Revenue • ($26M) EBITDA impact . Total Investments in business of ~$8M • - 2022 Investments Innovations & Projects ($3M) – spend related to automation, workforce optimization and roll out of Medalogix/Muse product • De Novos ($5M) - Expansion of de novo program 18

View entire presentation